Haemonetics Corporation (HAE) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Haemonetics said it achieved its prior long-range plan targets, including double-digit revenue growth ex-CSL, high-teens EPS and earnings growth, a 660 bps improvement in operating margin to the mid-20s, and nearly $700M of free cash flow. Management framed the result as evidence the company has moved successfully past the CSL transition and is now setting a new guide. The update is constructive for fundamentals, but it is primarily a strategy and performance recap rather than a new catalyst.

Analysis

HAE’s setup looks less like a cyclical re-rating and more like a de-risking of a previously complex story: once a company proves it can absorb a major revenue headwind and still expand margins, the market typically starts valuing the remaining core at a higher multiple. The second-order effect is that “execution beta” should compress; investors who were paying for turnaround optionality may now pivot to quality and cash conversion, which is supportive for the stock even if near-term growth decelerates. That also matters competitively: suppliers and channel partners will likely face a more disciplined customer that is now optimizing for profitability, not just top-line recovery.

The key question is whether the next leg is driven by further margin expansion or by capital allocation. If the core franchise is already in the mid-20s operating margin range, incremental upside becomes more about free cash flow durability, buybacks, and bolt-on tuck-ins than about another large operational step-up. That changes the valuation math: the stock can keep grinding higher over months, but the easiest gains should come on evidence that cash flow is being returned aggressively rather than reinvested into low-ROIC growth.

The main risk is that the market extrapolates the prior cadence too linearly. In medtech, post-disruption normalization often creates a 1-2 quarter air pocket where reported growth looks less exciting even as underlying profitability remains healthy; that’s where multiples can compress if investors are expecting a straight-line beat-and-raise. A sharper-than-expected slowdown in procedure volumes or any pricing pressure from hospital purchasing groups would matter more now because the story has shifted from recovery to sustainment.

Consensus may be underappreciating how much of the upside is already visible in the operating model, while underpricing the durability of cash generation. The opportunity is not in chasing a growth name, but in owning a self-funding compounder whose downside is buffered by improved margins and balance sheet flexibility. If management uses the new guide to signal disciplined capital returns, the stock can behave more like a cash-yielding healthcare quality name than a turnaround, which would justify another rerating over the next 6-12 months.

Key Decisions for Investors

• Long HAE on a 3-6 month horizon into any post-conference pullback; thesis is multiple expansion from proven execution and cash flow conversion, with downside limited if margins hold in the mid-20s.
• Use a call spread in HAE (3-9 months) rather than outright stock if positioning is already crowded; captures rerating upside while limiting drawdown if the market demands a digestion quarter.
• Pair HAE long vs. a lower-quality medtech peer with weaker margin conversion and more leverage; the trade should work over 1-2 quarters if investors rotate toward self-funding compounders.
• Trim/add rule: if HAE trades as if the market is assuming another step-function beat, reduce exposure after the next earnings print unless management explicitly raises capital return targets.
• If procedure-volume indicators soften, hedge HAE with a broad healthcare ETF short over 1-2 months; the stock’s new valuation depends more on sustainment than on additional turnaround torque.